Unlock instant, AI-driven research and patent intelligence for your innovation.

Xanthine derivatives

A compound, selected from the technology, applied in the field of dipeptidyl peptidase IV inhibitors

Active Publication Date: 2016-11-23
CHENGDU EASTON BIOPHARMACEUTICALS CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although several DPP-IV inhibitors have been marketed, such as sitagliptin phosphate, vildagliptin, alogliptin benzoate, etc., they are all administered once a day. In order to increase patient compliance, it takes a week DPP-IV inhibitors that are administered once, so there is still a clinical need for new long-acting DPP-IV inhibitors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Xanthine derivatives
  • Xanthine derivatives
  • Xanthine derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052]

[0053] Synthesis of the first step compound 1a

[0054] Using known methods, 8-bromo-3-methylxanthine (5g, 20.4mmol) was dissolved in N,N-dimethylformamide (30ml), N,N diisopropylethylamine (2.633 g, 20.4mmol), 1-bromo-2-butyne (2.714g, 20.4mmol), react overnight at room temperature, follow the reaction process by thin-layer chromatography, after the reaction is complete, pour the reaction solution into water, filter with suction, and wash the solid with water for 3 times, dried to obtain 1a (5.15g, pale yellow solid), yield: 85%.

[0055] MS m / z(ES):297,299[M+1]

[0056] Synthesis of the second step compound 1b

[0057] Using a known method, 1a (156 mg, 0.53 mmol) was dissolved in N,N dimethylformamide (3 ml), and 2-bromomethyl-5-fluoro-1,3-benzothiazole (140 mg, 0.57 mmol), potassium carbonate (118mg, 0.79mmol), reacted overnight at room temperature, after the reaction was completed by thin-layer chromatography, poured into water, filtered with suction, washed...

Embodiment 2

[0070]

[0071] The first step is the same as the first step in implementation example 1;

[0072] The second step is the same as the implementation example 1 second step;

[0073] The third step is the same as the third step of implementation example 1;

[0074] The fourth step is the same as the fourth step of implementation example 1;

[0075] Synthesis of the fifth step compound 2

[0076] Using a known method, compound 1d (140mg, 0.29mmol) and triethylamine (44mg, 0.44mmol) were dissolved in dichloromethane (4ml), and diethyl chlorophosphate (50mg, 0.29mmol) was added dropwise in an ice-water bath ). After dropping, react overnight at room temperature, and track the reaction by thin-layer chromatography, which shows that the raw materials are completely consumed. The reaction solution was washed with saturated brine, separated, dried, concentrated and purified by preparative thin-layer chromatography (dichloromethane:methanol=10:1) to obtain the product compound 2 ...

Embodiment 3

[0080]

[0081] The first step is the same as the first step in implementation example 1;

[0082] The second step is the same as the implementation example 1 second step;

[0083] The third step is the same as the third step of implementation example 1;

[0084] The fourth step is the same as the fourth step of implementation example 1;

[0085] Synthesis of the fifth step compound 3e

[0086] Using a known method, compound 1d (2.4g, 4.99mmol) was dissolved in dichloromethane (50ml), and N-Boc-L-alanine (940mg, 4.97mmol), dicyclohexylcarbodiimide, and (1.23g, 5.97mmol), 1-hydroxybenzotriazole (800mg, 5.93mmol), sodium carbonate (1.1g, 10.38mmol), react overnight at room temperature, follow the reaction by thin layer chromatography, showing that the raw materials are completely consumed, filter, di The filter cake was washed with methyl chloride (30ml*3), the filtrate was concentrated and purified by column chromatography to obtain the product compound 3e (2.4g, yellow s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses xanthine derivatives and isomers. Through normal mice sugar tolerance influence tests and beagle dog in-vivo DPP-IV activity inhibition tests, the compounds show excellent DPP-IV inhibition activity, and are applicable to prepare medicines for treating diseases correlated to dipeptidyl peptidase IV.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a class of xanthine derivatives, a preparation method and the use of the derivatives as a therapeutic drug administered once a week, especially as a dipeptidyl peptidase IV (DPP-IV) inhibitor. Background technique [0002] Diabetes mellitus is a metabolic disease of multiple etiologies characterized by chronic hyperglycemia accompanied by disturbances in carbohydrate, fat and protein metabolism due to defects in insulin secretion and / or action. Diabetes is also a very old disease, which is due to the relative or absolute lack of insulin in the human body, which causes the blood glucose concentration to rise, resulting in a large amount of sugar being excreted from the urine, accompanied by polydipsia, polyuria, polyphagia, weight loss, and dizziness , fatigue and other symptoms. [0003] In diabetes treatment, exercise therapy and diet therapy are two essential diabetes treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D473/04C07F9/6561A61P3/10
CPCC07D473/04C07F9/65616
Inventor 王颖向永哲岑国栋
Owner CHENGDU EASTON BIOPHARMACEUTICALS CO LTD